Completed OBSERVATIONAL NCT00150891

Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection

Role of Th1, Th2 and Monokine Responses as Risk Factors of Acute and Chronic Renal Transplant Rejection - Impact of Different Immunosuppressive Protocols

Sponsor: Astellas Pharma Inc

Conditions Renal Failure, Chronic

Interventions Kidney transplantation azathioprine cyclosporine A mycophenolate mofetil tacrolimus

Updated 7 times since 2017 Last updated: May 8, 2007 Started: Jan 31, 1998 Completion: Jan 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Renal Failure, Chronic and is currently completed. Astellas Pharma Inc leads this study, which shows 7 recorded versions since 1998 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Sep 2020 — Jan 2021 [monthly]

Completed
Jun 2018 — Sep 2020 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jan 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc
Biotest
Fresenius AG
Heidelberg University
Hoffmann-La Roche
Novartis
University of Giessen

Data source: University of Giessen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Giessen, Germany